Bicycle Therapeutics is pioneering first in class therapeutics to treat cancer and other debilitating diseases based on its proprietary bicyclic peptides (Bicycles®) platform.
Bicycles are a breakthrough new therapeutic class that combine antibody-like affinity and selectivity with small molecule-like tissue penetration, tuneable exposure, flexible pharmacokinetics and chemical synthesis.
Bicycle Therapeutics is rapidly advancing towards the clinic with its lead programme using a Bicycle Drug Conjugate® with Cancer Research UK to selectively deliver toxin to tumours. Bicycle is also exploring the potential of bicyclic peptides as targeted, titratable and rapidly penetrant immunomodulators, overcoming the challenges seen for other agents with long exposure, irreversible effects and attendant toxicities. The company's primary focus is oncology but it is also working in other areas, such as respiratory and cardiovascular and metabolic disease, through a significant partnership with AstraZeneca, to realise the full therapeutic potential of the Bicycle technology.
Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the Medical Research Council Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company: Sir Greg Winter, a pioneer in monoclonal antibody development, and Professor Christian Heinis, an accomplished researcher in the field of peptide therapeutics.
This technology allows phage presentation of linear precursor peptides, followed by an on-phage chemical cyclisation to generate enormously diverse structurally constrained Bicycle libraries. These libraries, which can be varied by loop size, symmetry and scaffolding agent, can then be screened against almost any soluble or cell based target using the proprietary Bicycle screening process.
Bicycle Therapeutics is headquartered in Cambridge, U.K. and has U.S. operations in Cambridge, Massachusetts.